"Advance Neuren’s strategy to commercialise trofinetide outside North America, including Europe and Japan
* Engage with regulators to confirm requirements for registration in Rett syndrome
* Progress partnering discussions"
Would seem that a takeover is not on the cards.
Ann: Presentation at AusBiotech Invest and Partnering 2018, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
-0.290(1.73%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.58 | $16.74 | $16.40 | $9.107M | 549.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 864 | $16.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.50 | 1668 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |